Nordea Investment Management AB Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Nordea Investment Management AB increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 47.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,405,281 shares of the medical research company's stock after buying an additional 452,029 shares during the quarter. Nordea Investment Management AB owned 0.77% of IQVIA worth $277,908,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC increased its stake in shares of IQVIA by 4.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 24,808 shares of the medical research company's stock worth $5,246,000 after purchasing an additional 952 shares in the last quarter. National Bank of Canada FI increased its position in IQVIA by 22.1% in the second quarter. National Bank of Canada FI now owns 52,580 shares of the medical research company's stock worth $10,962,000 after buying an additional 9,521 shares in the last quarter. Arizona State Retirement System lifted its position in shares of IQVIA by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 52,766 shares of the medical research company's stock valued at $11,157,000 after buying an additional 394 shares in the last quarter. Private Advisor Group LLC grew its stake in shares of IQVIA by 8.1% during the 2nd quarter. Private Advisor Group LLC now owns 5,078 shares of the medical research company's stock valued at $1,074,000 after acquiring an additional 379 shares during the period. Finally, Lake Street Advisors Group LLC increased its holdings in IQVIA by 80.7% in the 2nd quarter. Lake Street Advisors Group LLC now owns 2,421 shares of the medical research company's stock worth $512,000 after acquiring an additional 1,081 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IQV shares. TD Cowen lowered their price target on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Robert W. Baird lowered their target price on shares of IQVIA from $213.00 to $212.00 and set a "neutral" rating on the stock in a research note on Wednesday, December 11th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective on the stock. Finally, Leerink Partners reiterated an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $255.82.

IQVIA Trading Up 0.8 %

Shares of NYSE:IQV traded up $1.67 during trading on Monday, hitting $199.06. The company had a trading volume of 1,462,922 shares, compared to its average volume of 1,005,107. The stock has a market cap of $36.13 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a fifty day simple moving average of $202.86 and a two-hundred day simple moving average of $222.14. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.